Protease inhibitor for children with HIV and AIDS
Tags: AIDS (Disease) in children -- Treatment; PROTEASE inhibitors; ABBOTT Laboratories Inc.
Related Articles
- ABT-378 LOWERS VIRAL LOAD. // AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p199
Reports on the results of a preliminary study done on Abbott Laboratories' ABT-378 second-generation protease inhibitor. Reduction in viral loads; Impact of ritonavir on the bioavailability of ABT-378.
- SOFT-GEL NORVIR. // AIDS Patient Care & STDs;Jul99, Vol. 13 Issue 7, p437
Reports on Abbott Laboratories' request to the United States Food and Drug Administration to approve a soft-gel capsule formulation of protease inhibitor Norvir, following the use of liquid formulations due to its limited supply.
- Abbot plans for Norvir capsule shortage. // Drug Store News;8/24/98, Vol. 20 Issue 13, pCP10
No abstract available.
- NDA for ritonavir. // Drug Topics;2/5/96, Vol. 140 Issue 3, p28
Reports on the submission of a New Drug Application by Abbott Laboratories for the ritonavir protease inhibitor.
- AIDS Drug Pricing. Wechsler, Jill // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p22
The article reports that the Doctors Without Borders has criticized Abbott Laboratories for not making available immediately its heatstable tablet of protease inhibitor Kaletra, at a discounted third-world price of $500 per patient per year. According to the article, the drug was approved by the...
- Will once-daily Kaletra be enough to see off the threat of Reyataz? // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p33
No abstract available.
- Abbott Labs wins FDA approval for AIDS drug. // Advertising Age;3/4/1996, Vol. 67 Issue 10, p2
Reports that Abbott Laboratories received approval from the United States Food & Drug Administration for retonivir, a protease inhibitor to be used in the treatment of AIDS and to be marketed as Norvir. Other companies who have gotten or hope to get approval for protease inhibitors.
- Lower-strength antiretroviral is sanctioned. // Contemporary Pediatrics;Dec2007, Vol. 24 Issue 12, p15
The article reports on the marketing approval received by Abbott Laboratories from the U.S. Food and Drug Administration (FDA) for a lower-strength version of the Human immunodeficiency virus (HIV) protease inhibitor lopinavir/ritonavir named Kaletra. The lower-strength version of Kaletra is...
- Abbott Patent Affirmed. Lam, Michael D. // Pharmaceutical Executive;Sep2004, Vol. 24 Issue 9, p20
Reports on the affirmation of the patent on AIDS drug Norvir from Abbott Laboratories Inc. by the U.S. National Institutes of Health. Price of the drug; Efficacy of other protease inhibitors; Competition of drugs in the market.
